Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Neumega, Interleukin-11 (IL-11)
Biological Response Modulator, Thrombopoeitic Growth Factor
Original Date: 
October 2007
  • Prevention of severe thrombocytopenia and reduction of need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia
Reconstitution and Stability: 
  • Available as a sterile powder (5 mg) packaged with diluent (1 mL of SWI).
  • Refrigerate vials.  Do not freeze. Protect from light.
  • Reconstitute with provided diluent (SWI) to a final concentration of 5 mg/mL. Gently swirl, do not shake.
  • Reconstituted solution stable for 3 hours refrigerated or at room temperature.
  • Oprelvekin should not be mixed with other solutions or medications.

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC YES    abdomen,thigh,hip or upper arm
IV Direct NO
IV Intermittent Infusion NO
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Note: First dose should not be administered until 6-24 hours after the end of chemotherapy. Discontinue the drug at least 48 hours before beginning next cycle of chemotherapy.


 Children (>12 yrs)

·          75-100 mcg/kg once daily subcutaneously for 10-21 days (until post-nadir of platelet count > 50 x109/L)

·          Manufacturer states that, until efficacy/toxicity parameters are established use of Oprelvekin should be limited to pediatric patients in controlled clinical trials.






·          50 mcg/kg once daily subcutaneously for 10-21 days (until post-nadir of platelet count >50 x109/L)

 Dosage adjustment in renal failure (adults)

  • CLcr < 30 mL/min : 25 mcg/kg
Potential hazards of parenteral administration: 
  • Hypersensitivity reactions (anaphylaxis, dyspnea, flushing and/or chest pain).
  • Serious fluid retention (mean increase of >20% in plasma volume)
  • Cardiovascular: Tachycardia (children: 84%), palpitation, atrial arrhythmias, peripheral edema, syncope, stroke, cardiomegaly (children: 21%), CHF, palpitations, pericardial effusion
  • Respiratory: Dyspnea, pleural effusion, pulmonary edema, capillary leak syndrome, pneumonia, rhinitis, cough, pharyngitis
  • Dilution anemia
  • Hypokalemia (mostly in patients requiring chronic diuretic therapy)
  • Other side effects include: nausea, vomiting, headache, dizziness, insomnia, fatigue, fever arthralgia, myalgia, rash, skin discoloration papilledema (up to 16% in children, 2% in adults), visual disturbance, conjunctival injection (children: 57%), renal failure
  • Have anaphylactic kit available at bedside.
  • Monitor vital signs (Pulse, Resp. Rate, BP, Temp) Q15 minutes x 4 after administration, then Q30 minutes x 2    
  • Not indicated following myeloablative chemotherapy: increased toxicity and severe/fatal adverse reactions reported.
  • Monitor: CBC, diff, electrolytes and fluid balance, calcium, creatinine, BUN.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.